Mesothelin-related predictive and prognostic factors in malignant mesothelioma: a nested case-control study.

[1]  Claudio Bianchi,et al.  Malignant mesothelioma: global incidence and relationship with asbestos. , 2007, Industrial health.

[2]  A. Andersen,et al.  Absence of SV40 antibodies or DNA fragments in prediagnostic mesothelioma serum samples , 2007, International journal of cancer.

[3]  M. Copin,et al.  Utility of Osteopontin and Serum Mesothelin in Malignant Pleural Mesothelioma Diagnosis and Prognosis Assessment , 2007, Clinical Cancer Research.

[4]  N. Sardesai,et al.  MESOMARK: a potential test for malignant pleural mesothelioma. , 2007, Clinical chemistry.

[5]  Y. Takeshima,et al.  Immunohistochemical marker panels for distinguishing between epithelioid mesothelioma and lung adenocarcinoma , 2007, Pathology international.

[6]  Mitchell Ho,et al.  Releasable PEGylation of mesothelin targeted immunotoxin SS1P achieves single dosage complete regression of a human carcinoma in mice. , 2007, Bioconjugate chemistry.

[7]  B. Garvik,et al.  Development of a CA125-mesothelin cell adhesion assay as a screening tool for biologics discovery. , 2007, Cancer letters.

[8]  Mitchell Ho,et al.  Mesothelin Expression in Human Lung Cancer , 2007, Clinical Cancer Research.

[9]  Mitchell Ho,et al.  Mesothelin-MUC16 binding is a high affinity, N-glycan dependent interaction that facilitates peritoneal metastasis of ovarian tumors , 2006, Molecular Cancer.

[10]  Mitchell Ho,et al.  Mesothelin Is Shed from Tumor Cells , 2006, Cancer Epidemiology Biomarkers & Prevention.

[11]  S. Pandita Banning Asbestos in Asia: Campaigns and Strategies by the Asian Network for the Rights of Occupational Accident Victims (ANROAV) , 2006, International journal of occupational and environmental health.

[12]  M. Copin,et al.  Soluble mesothelin-related peptides in the diagnosis of malignant pleural mesothelioma. , 2006, American journal of respiratory and critical care medicine.

[13]  N. Sardesai,et al.  Mesothelin Variant 1 Is Released from Tumor Cells as a Diagnostic Marker , 2006, Cancer Epidemiology Biomarkers & Prevention.

[14]  A. Gown,et al.  Evaluation of 12 antibodies for distinguishing epithelioid mesothelioma from adenocarcinoma: identification of a three-antibody immunohistochemical panel with maximal sensitivity and specificity , 2006, Modern Pathology.

[15]  S. Rubin,et al.  Screening for ovarian cancer in the general population. , 2006, Best practice & research. Clinical obstetrics & gynaecology.

[16]  A. Olshen,et al.  Global gene expression profiling of pleural mesotheliomas: overexpression of aurora kinases and P16/CDKN2A deletion as prognostic factors and critical evaluation of microarray-based prognostic prediction. , 2006, Cancer research.

[17]  I. Shih,et al.  Diffuse Mesothelin Expression Correlates with Prolonged Patient Survival in Ovarian Serous Carcinoma , 2006, Clinical Cancer Research.

[18]  Alan T. Remaley,et al.  Detection and Quantitation of Serum Mesothelin, a Tumor Marker for Patients with Mesothelioma and Ovarian Cancer , 2006, Clinical Cancer Research.

[19]  J. Creaney,et al.  Detection of malignant mesothelioma in asbestos-exposed individuals: the potential role of soluble mesothelin-related protein. , 2005, Hematology/oncology clinics of North America.

[20]  S. Touloupidis,et al.  Serum CYFRA 21-1 in patients with invasive bladder cancer and its relevance as a tumor marker during chemotherapy. , 2005, The Journal of urology.

[21]  Wei Zhang,et al.  Application of serum SELDI proteomic patterns in diagnosis of lung cancer , 2005, BMC Cancer.

[22]  R. Gaafar,et al.  Epidemic of mesothelioma in Egypt. , 2005, Lung cancer.

[23]  R. Jensen,et al.  Validation of Genomics-Based Prognostic Tests in Malignant Pleural Mesothelioma , 2005, Clinical Cancer Research.

[24]  K. Ohtsubo,et al.  Expression of Mesothelin mRNA in Pure Pancreatic Juice From Patients With Pancreatic Carcinoma, Intraductal Papillary Mucinous Neoplasm of the Pancreas, and Chronic Pancreatitis , 2005, Pancreas.

[25]  H. Grassos,et al.  The significance of CA125 levels in patients with chronic congestive heart failure. Correlation with clinical and echocardiographic parameters , 2005, European journal of heart failure.

[26]  J. Mate,et al.  Usefulness of tumor markers CA 125 and CA 15.3 at diagnosis and during follow-up in non-Hodgkin's lymphoma: study of 200 patients , 2005, Leukemia & lymphoma.

[27]  E. Hovig,et al.  BRCA1 mutations in ovarian cancer and borderline tumours in Norway: a nested case–control study , 2004, British Journal of Cancer.

[28]  N Urban,et al.  Combining CA 125 and SMR serum markers for diagnosis and early detection of ovarian carcinoma. , 2004, Gynecologic oncology.

[29]  I. Pastan,et al.  Mesothelin , 2004, Clinical Cancer Research.

[30]  N. Umesaki,et al.  Binding of Ovarian Cancer Antigen CA125/MUC16 to Mesothelin Mediates Cell Adhesion* , 2004, Journal of Biological Chemistry.

[31]  K. Müller,et al.  Factors influencing long-term survival in mesothelioma patients—results of the German mesothelioma register , 2004, International archives of occupational and environmental health.

[32]  E. Bleecker,et al.  Changing patterns in asbestos-induced lung disease. , 2004, Chest.

[33]  A. Musk,et al.  Mesothelin-family proteins and diagnosis of mesothelioma , 2003, The Lancet.

[34]  N. Ordóñez,et al.  Application of Mesothelin Immunostaining in Tumor Diagnosis , 2003, The American journal of surgical pathology.

[35]  Claude Denham,et al.  Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[36]  Ken Takahashi,et al.  A Cross-country Comparative Overview of the Asbestos Situation in Ten Asian Countries , 2003, International journal of occupational and environmental health.

[37]  A. Hjerpe,et al.  Growth factors regulate the expression profile of their syndecan co-receptors and the differentiation of mesothelioma cells. , 2003, Anticancer research.

[38]  B. Adapinar,et al.  CT findings and serum ca 125 levels in malignant peritoneal mesothelioma: report of 11 new cases and review of the literature , 2003, European Radiology.

[39]  P. Baas Predictive and prognostic factors in malignant pleural mesothelioma , 2003, Current opinion in oncology.

[40]  A. Gazdar,et al.  SV40 and human tumours: myth, association or causality? , 2002, Nature Reviews Cancer.

[41]  I. Uçgun,et al.  Malignant mesothelioma due to environmental exposure to asbestos: follow-up of a Turkish cohort living in a rural area. , 2002, Chest.

[42]  K. O'Byrne,et al.  Cyclooxygenase-2 expression is a novel prognostic factor in malignant mesothelioma. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[43]  J. Leigh,et al.  Malignant mesothelioma in Australia, 1945-2000. , 2002, American journal of industrial medicine.

[44]  N. Siafakas,et al.  Prognostic Value of Serum Tumor Markers in Patients with Lung Cancer , 2002, Respiration.

[45]  P. Clement,et al.  Diffuse malignant epithelial mesotheliomas of the peritoneum in women , 2002, Cancer.

[46]  I. Uçgun,et al.  Prognostic factors in diffuse malignant pleural mesothelioma: effects of pretreatment clinical and laboratory characteristics. , 2001, Respiratory medicine.

[47]  S. Parodi,et al.  Diagnostic value of CYFRA 21-1 tumor marker and CEA in pleural effusion due to mesothelioma. , 2001, Chest.

[48]  J. Testa,et al.  Genetic-susceptibility factor and malignant mesothelioma in the Cappadocian region of Turkey , 2001, The Lancet.

[49]  E. Glattre,et al.  Effect of long-term storage on the concentration of albumin and free fatty acids in human sera , 2001, Scandinavian journal of clinical and laboratory investigation.

[50]  A. Hjerpe,et al.  An optimized battery of eight antibodies that can distinguish most cases of epithelial mesothelioma from adenocarcinoma. , 2000, American journal of clinical pathology.

[51]  A. van Dalen,et al.  A profile of tumor markers in the population of Kuwait. , 1999, Anticancer research.

[52]  B. Weyn,et al.  Syndecan‐1 expression in malignant mesothelioma: correlation with cell differentiation, WT1 expression, and clinical outcome , 1998, The Journal of pathology.

[53]  J. Herndon,et al.  Factors predictive of survival among 337 patients with mesothelioma treated between 1984 and 1994 by the Cancer and Leukemia Group B. , 1998, Chest.

[54]  H. Bruckner,et al.  Tumor markers in patients with pancreatic carcinoma , 1996, Cancer.

[55]  S. Constantopoulos,et al.  Malignant pleural mesothelioma from nonoccupational asbestos exposure in Metsovo (north-west Greece): slow end of an epidemic? , 1996, The European respiratory journal.

[56]  I. Pastan,et al.  Molecular cloning of mesothelin, a differentiation antigen present on mesothelium, mesotheliomas, and ovarian cancers. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[57]  A. Andersen,et al.  Experiences of the Janus Serum Bank in Norway. , 1995, Environmental health perspectives.

[58]  C. Muirhead,et al.  Residential radon exposure and lung cancer—an epidemiological study of Norwegian municipalities , 1994, International journal of cancer.

[59]  A. van Dalen,et al.  Reference levels of the tumor markers carcinoembryonic antigen, the carbohydrate antigens 19-9 and 72-4, and cytokeratin fragment 19 using the Elecsys Relecsys 1010 analyzer in a normal population in Kuwait. The importance of the determination of local reference levels. , 2002, The International journal of biological markers.